Targeted gene transduction to organs and tissues of interest is the ultimate goal of therapeutic gene delivery. Lentiviral vectors (LVs) are powerful tools for stable gene delivery but their integration into undesired cell types poses a serious safety concern for their use in the clinic. Here we report the development of a new dual-targeted LV that can preferentially home to and express in prostate cancer bone metastases in vivo after systemic delivery. Transductional targeting is mediated by a modified Sindbis virus envelope that interacts with the prostate stem cell antigen (PSCA) expressed by prostate cancer cells, and transcriptional targeting is mediated by a prostate cell specific promoter. Homing to prostate tumors was achieved in 70% of the animals. Importantly, tumors could be detected in some cases by molecular imaging prior to X-ray detection. The dual-targeted vector presents enhanced specificity with respect to individual transcriptional or transductional targeted vectors. Transgene expression in the liver was 190 times lower than the expression associated with solely transductionally targeted vectors, and there was 12 times less vector DNA than the amount present with solely transcriptionally targeted vectors. The LV presented here is a powerful tool for obtaining stable and site-specific gene expression and can be easily modified for its use in other diseases.
Targeted gene transduction to organs and tissues of interest is the ultimate goal of therapeutic gene delivery. Lentiviral vectors (LVs) are powerful tools for stable gene delivery but their integration into undesired cell types poses a serious safety concern for their use in the clinic. Here we report the development of a new dual-targeted LV that can preferentially home to and express in prostate cancer bone metastases in vivo after systemic delivery. Transductional targeting is mediated by a modified Sindbis virus envelope that interacts with the prostate stem cell antigen (PSCA) expressed by prostate cancer cells, and transcriptional targeting is mediated by a prostate cell specific promoter. Homing to prostate tumors was achieved in 70% of the animals. Importantly, tumors could be detected in some cases by molecular imaging prior to X-ray detection. The dual-targeted vector presents enhanced specificity with respect to individual transcriptional or transductional targeted vectors. Transgene expression in the liver was 190 times lower than the expression associated with solely transductionally targeted vectors, and there was 12 times less vector DNA than the amount present with solely transcriptionally targeted vectors. The LV presented here is a powerful tool for obtaining stable and site-specific gene expression and can be easily modified for its use in other diseases.
IntroductIon
Gene therapy involves the delivery of recombinant genetic material to cells and tissues to combat disease. In vivo gene therapy has been limited largely by inefficient delivery systems and lack of specificity, two drawbacks that have been the focus of extensive research efforts in recent years but remain the greatest hurdles to the applicability of gene therapy. The ideal delivery system would be easy to produce, easy to administer, and non-toxic to normal cells; it would deliver the genetic information efficiently and specifically via the bloodstream to the targeted tissues and integrate the genetic material into the host cell so that the transgene would be stably expressed. Integration of the vector genome into target cells allows stable expression, but also poses potential safety problems caused by insertional mutagenesis. It is therefore of the utmost importance that it be restricted specifically to tissues in need of treatment. In light of the fact that 3 cases of leukemia caused by gene activation following vector integration have been reported in patients treated for X-linked severe combined immunodeficiency (SCID), 1,2 a need has arisen to reassess the safety of gene therapy strategies. The expression of therapeutic transgenes in cells other than the targeted ones may also give rise to significant deleterious effects and should therefore be minimized. These two requisites pose a particular challenge for the systemic delivery of gene therapy vectors. Many attempts have been made to limit the expression of transgenes by introducing specific promoters into lentiviral vectors (LVs); however, most vectors are pseudotyped with envelopes that have a broad host range (such as vesicular stomatitis virus glycoprotein (VSV-G)) and consequently they may potentially enter all cells of an organism, and their genome become integrated in the cells. The development of approaches that allow for expression of transgenes only in appropriate target cells by utilizing a combination of targeted transduction 3 and cell type-specific expression will increase the overall safety and applicability of gene therapy.
We previously described a LV targeted at the transductional level through pseudotyping with modified Sindbis virus envelope proteins. The distinguishing properties of this vector relative to past retroviral targeting vectors were that it could be produced in high titers and home to specific cells and tissues after systemic administration via the bloodstream. We demonstrated preferential targeting to melanoma in vivo after intravenous injection. 4 However, the transcription of the transgene was ubiquitous and resulted in residual expression in non-melanoma tissues, primarily liver and spleen. Here, we describe a LV that has been engineered at two levels to synergistically enhance specificity of transgene expression. As a proof of concept, the dual-targeted vector was used for targeting bone metastases of prostate cancer. Transductional targeting was achieved by pseudotyping the vector with a modification of the previously described Sindbis envelope protein (2.2) that can direct infection via monoclonal antibodies, and transcriptional targeting was achieved with a prostate specific antigen promoter called PSE-BC that drives expression preferentially in prostate cells. [5] [6] [7] [8] Prostate cancer is the most common malignancy diagnosed in males and is currently the second leading cause of cancer-related death among men in the United States. 9 Eighty percent of prostate cancer patients develop bony metastases, 10 of which up to 95% are osteoblastic and characterized by the deposition of dense, sclerotic bone. 11 These metastases are a considerable source of morbidity and result in serious clinical complications and a decrease in patient survival rate. The treatment of bone metastases is an extremely challenging endeavor because of the anatomical structure of bone, the reciprocal interaction between tumor cells and bone, and because a patient will often have multiple metastatic lesions. Also, skeletal metastases are the most resistant to treatment, present the highest bulk of tumor mass in the body and serve as sites for secondary spread of tumor cells. Therefore, there is a pressing need for more effective delivery of anti-cancer drugs to the skeletal system, 12 making it an ideal setting for gene therapy using novel delivery platforms that will improve treatment efficacy and reduce side effects.
We describe targeting of the dual-targeted LV in a model of osteoblastic prostate cancer bone metastases that recapitulates human pathology. 9, [13] [14] [15] In this intratibial model of metastasis, LAPC-9 prostate cancer cells originally derived from a patient's femoral metastasis 16 are injected into the proximal tibia where they form an osteoblastic lesion that eventually invades the soft tissue of the leg. The LAPC-9 xenograft has been extensively used to study prostate cancer development and bone metastases in vivo. 8, [13] [14] [15] [16] [17] [18] This is the first report of a dual-targeted LV. We show that it can effectively target bone metastases in vivo after injection into the bloodstream and poses an advantage over transcriptionally or transductionally targeted vectors. In principle, this approach would be applicable to target a wide range of pathologic conditions by utilizing different monoclonal antibodies and promoters. results Prostate specific expression in vitro and in vivo from lentiviral vectors encoding Pse-Bc promoter The PSE-BC promoter contains the prostate specific antigen proximal promoter and a duplication of the core enhancer elements inserted 200 basepairs upstream of the proximal promoter. 8 We introduced this promoter into a third generation self-inactivating LV, driving the expression of enhanced green fluorescent protein (EGFP) or humanized firefly luciferase as reporter genes. The specificity of the promoter in our lentiviral system was analyzed by transducing different prostate and nonprostate cell lines with VSV-G pseudotyped vectors carrying PSE-BC or the ubiquitously expressed ubiquitin-C (Ubi-C) promoter (Figure 1) . The intensity of EGFP expression from PSE-BC was comparable to that of the Ubi-C promoter in prostate cell lines, and between 25 and 70 times lower in non-prostate cell lines and primary cells. Expression from PSE-BC was inducible by androgen only in prostate cell lines (Supplementary Figure  S1) as expected, due to the androgen response elements present in the promoter, whereas expression from the Ubi-C promoter was not induced (data not shown). Luciferase expression was between 9 and 7,000 times higher in prostate cell lines than in the other cell lines analyzed, having the highest background in primary fibroblasts and the lowest in primary human macrophages and peripheral blood mononuclear cells (PBMCs) (Supplementary Figure S1) .
Promoter specificity was then assayed in vivo utilizing xenograft models of human kidney 293T cells and LAPC-9 prostate cancer cells. LAPC-9 cells do not survive ex vivo and therefore could not be used for the in vitro studies described earlier, but they are extremely relevant for our studies because they are derived from a bone metastasis of a prostate cancer patient. 16 Four mice per group were used for both 293T and LAPC-9 experiments (Figure 2a and b) . Expression in the LAPC-9 tumor was detectable from day 7 until the animals were sacrificed at maximum allowed tumor size (1.5 cm in diameter). Luciferase expression was constant in the animals that carried the Ubi-C promoter and increased over time in the PSE-BC group, but no significant difference in the amount of expression measured as maximum photon output was observed between the two groups on days 14 and 25 (Wilcoxon Rank sum test). On the other hand, expression from 293T tumors (maximum photon output) was between 350 and 2,500 times greater from the Ubi-C promoter than from PSE-BC, a difference that was statistically significant (P = 0.015, Wilcoxon Rank sum test) and was maintained from day 7 until the animals were sacrificed (Figure 2a) . The PSE-BC promoter was significantly more active in prostate cancer LAPC-9 cells than in 293T cells, and luciferase expression in tumors between 1.2 and 1.5 cm was, on an average, 130 times greater in LAPC-9 (P = 0.015, Wilcoxon Rank sum test).
In order to evaluate the activity of the PSE-BC promoter in non-tumoral cells in vivo, 3 naïve SCID mice were injected through the tail vein with VSV-G pseudotypes encoding firefly luciferase under the control of Ubi-C or PSE-BC respectively, and monitored for luciferase expression. The vectors were mixed with 10 times less VSV-G pseoudotyped LV encoding renilla luciferase under the control of the Ubi-C promoter to control for injection efficiency. Renilla luc was detected throughout the body in both animal groups, but firefly luciferase was detected only in the animals that carried the vector with Ubi-C promoter (Figure 2c ). Firefly luciferase luminescence observed in the animals that carried the PSE-BC vector was barely above the limit of detection and significantly lower than the expression from the Ubi-C promoter (P = 0.05, Wilcoxon Rank sum test), although after the animals were sacrificed and the organs extracted a small signal was detected in the spleen (Supplementary Figure S2) . The Ubi-C promoter drove detectable expression in the spleen (130 times higher than the expression in the PSE-BC promoter group), heart, lungs, liver, testes, and kidneys (Supplementary Figure S2) .
dual-targeted vectors synergistically enhance specificity
Even if a promoter is highly specific, vector DNA will integrate into all cells that are transduced. In order to limit potential toxicity caused by the integration of vector genomes into non-target cells, we combined the PSE-BC promoter vector with a targeting envelope that allows preferential homing to prostate cancer cells. The vector was pseudotyped with a modified Sindbis envelope that uses monoclonal antibodies to target specific cell surface molecules. This technology was developed by us and has been previously described. 4, 19, 20 The envelope used in this study, 2.2, differs from previous envelopes in that it carries a combination of all mutations previously characterized by us. Mutations 1, 6, and 8 in the E2 Sindbis envelope glycoprotein decreased the natural tropism of Sindbis and consequently the background infectivity while maintaining high vector titers, 4 and mutation of aminoacids 226 and 227 in the E1 protein to SG allowed E1 to mediate fusion in the absence of cholesterol in the target membrane 21 and increased tropism and infectivity of Sindbis pseudotyped vectors. 20 The specificity of infection of the dual-targeted vectors was compared with vectors targeted only transductionally or only transcriptionally. Transductional targeting was mediated by 1G8, 18 ,22 a monoclonal antibody that recognizes the prostate stem cell antigen (PSCA), which is greatly overexpressed in prostate cancers and some bladder and pancreatic cancers. [22] [23] [24] We determined that 1G8 mediated efficient and specific entry into the PSCA-expressing prostate cell line LPSCA4, by comparing targeting to this cell line and to LNCaP cells. LPSCA4 is a clone of LNCaP stably transfected with PSCA. 22 The only difference between these two cells lines is the ectopic expression of the PSCA receptor, and 1G8 mediates selective infection of LAPSC4 (Figure 3) . We next compared transgene expression in LPSCA4 with vector expression in non-prostate cell lines and primary cells (Figure 4a and b) . Specificity was synergistically increased with the dual-targeted vectors and expression in non-target cells was reduced up to 2.7 × 10 5 times in human primary endothelial cells (derived from human umbilical vein) as compared with LPSCA4. These results encouraged us to evaluate targeting efficiency with this novel dual-targeted LV in an in vivo model.
specific targeting of prostate cancer bone metastases in vivo
In order to evaluate the background infectivity of the newly developed 2.2 envelope in vivo, we injected vectors carrying flag-tagged luciferase under the control of the Ubi-C promoter (FUcfLW) into the tail veins of naïve male SCID mice, and analyzed luciferase expression in comparison with control VSV-G pseudotypes (Figure 5a) . Expression from the VSV-G pseudotype was widespread whereas luciferase expression from the 2.2 pseudotype was restricted to the spleen and liver and over 50 times lower as measured by maximum photon output, a difference that was statistically significant (P = 0.05, Wilcoxon Rank sum test). The brain, heart, lungs, kidneys, liver, spleen, prostate, and testes of the animals were extracted and one set of organs from each group was evaluated for ex vivo luciferase activity and presence of vector DNA. VSV-G peudotypes mediated delivery and luciferase expression in all organs except the brain, whereas the 2.2 enveloped vector was present only in spleen and liver, as previously described for other modified Sindbis envelopes 4 and very marginally in kidneys ( Table 1) .
We then attempted systemic targeting of prostate cancer bone metastases in vivo with vectors carrying flag-tagged luciferase under the control of the PSE-BC promoter (FPcfLW) pseudotyped with 2.2 envelope or with control VSV-G envelope. We chose LAPC-9 cells for this experiment because of their clinical relevance and also because LPSCA4 cells grow very poorly in mice and do not form bone metastases. The LAPC-9 model system has been widely used and entails surgical implantation of an LAPC-9 prostate cancer cell suspension into the metaphysis of the left tibia. [13] [14] [15] The animals are then monitored weekly with X-rays to control for osteoblastic lesion formation. LVs were injected 1 and 2 weeks after LAPC-9 cells and luciferase expression was monitored weekly from the time of injection with a cooled chargedcoupled device (CCCD) camera until the tumor reached 1.5 cm in diameter (33 days). Targeting to the bone lesion was observed in 11 out of 16 mice (70%) injected with the dual-targeted vector and in 4 out of 5 mice injected with the VSV-G pseudotyped vector (80%). No targeting was observed in control transductions performed with 2.2 pseudotypes in the presence of isotype control antibody (Figure 5b) . Background expression from untargeted tissues was higher in the animals injected with the VSV-G pseudotype, as observed in the whole mouse imaging with CCCD camera and in the pictures of the organs taken after the mice were sacrificed (Figure 5b) . Luciferase expression from the tumor was significantly higher than from background tissues for the doubletargeted group, measured both as maximum and as total photon output (P = 0.001, Wilcoxon Rank sum test) whereas in the VSV-G pseudotyped group the difference between targeted and untargeted organs was not significant (Supplementary Figure S3) . It is important to note that luciferase signal could be detected prior to the detection of the metastasis by X-ray in two of the animals from the double-targeted group (Figure 6) , thereby indicating that this technology could potentially be optimized as a tool to detect and treat early stage metastatic lesions before they become apparent through other diagnostic approaches.
The organs of three animals from the VSV-G group and four from the 2.2 + 1G8 group were processed for ex vivo luciferase detection and determination of the number of vector DNA copies ( Table 1) . The left hind limbs of between two and four animals per group were fixed and sectioned for histologic analysis. As expected from the broad host range of VSV-G, vector DNA from VSV-G pseudotypes was detected in all tissues analyzed, except the brain. Mice injected with 2.2 pseudotyped vectors had no detectable vector DNA copies in any tissue except the prostate tumor, spleen, and liver, in the latter two organs 4 and 12 times less DNA, respectively, than VSV-G pseudotypes. Vector DNA copy number and luciferase expression were reduced in the soft tissue tumor samples as compared with When the vector was injected into the animals, the LAPC-9 tumor was present only inside the bone. Invasion of the surrounding soft tissue occurred after vector administration, and it is possible that binding of 1G8 to PSCA and its subsequent internalization renders the transduced cells more dependent on factors in the bone microenvironment. Thus the most relevant data for evaluating the targeting efficiency are from the inside of 5 LAPC-9 cells were implanted into the left tibia of male SCID mice. On days 7 and 14 after implantation, FPcfLW (2.2) with 1G8 or isotype control monoclonal antibody, or FPcfLW (VSV-G) was injected through the tail vein. The groups consisted of 16, 5, and 5 mice respectively. Five mice were injected with phosphate-buffered saline as controls. Mice were imaged in a cooled charged-coupled device (CCCD) camera and X-rayed once a week for 33 days. The images shown are from day 33 and the X-rays of the left leg from day 30. CCCD imaging of two representative animals from each group are shown. X-ray and organs of animal #2 are shown. Bone, bones of the lower leg (tibia and fibula); tumor, soft tumor that surrounds the bone. Figure 6 luciferase expression can be detected in the metastasis before X-ray manifestation. X-ray and cooled charged-coupled device (CCCD) images of one animal between 2 and 5 weeks post LAPC-9 cell implantation in the tibia. FPcfLW (2.2) + 1G8 antibody was injected on weeks 1 and 2 after LAPC-9 cell injection. An optical signal can be detected at 3 weeks after cell implantation (1 week after the second vector injection), when there is no pathology apparent on the X-ray.
the bone samples, especially in the 2.2 + 1G8 group (Table 1) .
the bone where the tumor is growing under physiological conditions. Vector DNA in the bone ranged from 0.2% to 8% of the target cells transduced, and half of the animals that received the dual-targeted vector had as many copies as the ones that received VSV-G pseudotyped vectors. Luciferase expression in the liver from the dual-targeted vector was barely above the limit of detection. Furthermore, the ratios of both luciferase expression and amount of vector DNA in the bone compared to the spleen and liver were on average higher for the dual-targeted group than for the VSV-G group ( Table 1) . The contralateral legs of two animals injected with dual-targeted vectors were also analyzed and no ex vivo luciferase activity or integrated vector copies were detected.
Specific targeting to prostate tumors was also confirmed by immunofluorescence staining of the flag motif fused to the humanized luciferase. Flag stained colonies were apparent in slides obtained from animals injected with 2.2 pseudotypes and 1G8 targeting antibody whereas in sections from animals injected with 2.2 and isotype control antibody no positive colonies were detected. In sections obtained from animals injected with VSV-G pseudotypes luciferase expression was detected in human cells and, in some cases, in mouse cells, stressing the advantage of the double targeting, given that the restriction of protein expression by the promoter is not absolute (Figure 7) .
dIscussIon
The implementation of gene therapy in the clinic has been limited by the inability to deliver therapeutic genes exclusively to specific sites in vivo after systemic administration. If gene therapy is ever to attain its full potential, enhancement of vector safety is necessary, as evidenced by the serious side effects caused by insertional mutagenesis that have been observed in some clinical trials.
1,2 Current gene therapy applications involve ex vivo transduction of cells and reintroduction into patients, but many situations that would greatly benefit from gene therapy approaches are not amenable to such ex vivo cell manipulation. Here we present a technology that represents a significant improvement in specificity of gene delivery and allows in vivo targeting of tumor metastases after intravenous administration. Transgene expression of the dual-targeted vector is 1,000 times lower in the liver and 34 times lower in the spleen than that of a VSV-G pseudotype carrying Ubi-C promoter. The dual-targeting technology is more specific than transcriptional targeting alone; transgene expression is 190 times lower in the liver and two to three times lower in the spleen. It is also more specific than the transductional targeting alone; vector DNA copy number is 12 times lower in the liver and 3.5 times lower in the spleen. Several attempts have been made to direct specific transgene expression (77) 10 (23) Abbreviations: Ubi-C, ubiquitin-C; ud, undetectable; VSV-G, vesicular stomatitis virus glycoprotein; −, not applicable (these animals had no LAPC-9 tumor). a Organs were extracted and minced. Half of each organ was used for ex vivo luciferase analysis after protein extraction and genomic DNA was isolated from the other half and used as substrate for quantitative polymerase chain reaction. Protein and DNA isolation and analyses are described in Materials and Methods. b DNA values represent vector copies/10 4 cells. In all cases the copy number is calculated per mouse cell, except for the bone and tumor samples which were determined per human cell. The limit of detection for DNA copy number in each organ was, per 10 4 cells: 4.5 copies in the brain, 5 in the heart, 3 in the lung, 2 in the kidney, 7 in the liver, 4.5 in the spleen, 4.5 in the testes, 2 in the prostate, 2 in the leg and 3 in the tumor.
c RLU represents relative luciferase units ×10 3 /ng of protein in the sample.
d Bones of the lower left hind limb into which LAPC-9 cells were injected. e Soft tissue tumor is the LAPC-9 soft tumor present in the leg derived from cells migrating out of the tibia. after systemic delivery utilizing VSV-G pseudotypes carrying tissue-specific promoters. 7, 25, 26 In these studies, extensive DNA analyses were not performed and, although the expression of the transgene can be more or less specific depending on the promoter, integration will occur in every cell that can be transduced by the VSV-G envelope. In our studies, even though luciferase expression was not detected, VSV-G pseudotyped vectors were present in the spleen, liver, heart, lungs, kidneys, prostate, and testes in addition to being present in the tumor. The enhancement of specificity is associated with a decrease in overall expression at the targeted tissue, partly because a lower number of cells are transduced. This effect could be mitigated by introducing modifications to the promoter such as two-step transcriptional activation 6, 7 but ultimately this technology would be optimal in a setting where the transgene of interest is a secreted protein. In such a scenario, even if the number of transduced cells is limited, therapeutic concentration of the transgene could be achieved at the target tissue.
�-flag
The specific homing of a gene therapy vector to prostate bone metastases opens exciting new possibilities for treatment. Complete response of bone lesions to current treatment is very rare, in contrast with lesions in non-osseous sites, from which about 10-20% of patients achieve complete recovery. Anti-cancer therapies will undoubtedly benefit from the targeting of drug delivery, because this approach offers the potential to increase local bioavailability while reducing the dose needed for effective therapy, thereby reducing undesirable side effects. Ideally, therapeutic transgenes would be proteins that could be secreted into the bone-tumor microenvironment and would be able to inhibit proliferation of metastatic cells. When the prostate tumor cells reach the bone, they release pro-osteoblastic factors that stimulate osteoblast growth and bone remodeling. The result is a dramatic change in bone metabolism at the site of metastasis and secretion by the activated osteoblasts of a number of growth factors that allow tumor survival and growth in the bone microenvironment. The osteoblastic phenotype could be induced by one or several factors secreted by prostate cancer cells such as Wnt, endothelin-1 and bone morphogenetic proteins. 9, 12 One possible therapeutic gene which we are currently studying is the bone morphogenetic protein antagonist, noggin. Noggin has been shown to inhibit the growth of osteoblastic lesions in vivo 14 but would have deleterious side-effects if administered systemically, which makes it an ideal candidate for targeted gene delivery. Studies are underway to determine its effect on bone metastasis growth after delivery with a dual-targeted LV.
The vector technology presented here would be relatively easy to modify for other disease settings by changing the tissue-specific promoter and the targeting antibody. Further modifications of the Sindbis virus envelope protein that will allow this strategy to be implemented in immunocompetent animals are being developed in our laboratory and elsewhere. [27] [28] [29] Such approaches would involve direct cloning of single chain antibodies or peptides into the envelope protein. Further modifications of the promoter, especially to make it less active in spleen cells, will also be necessary, and are underway. One approach to reducing expression in spleen cells is to include target sequences for microRNAs in the vectors. These have been shown to suppress expression in hematopoietic lineages and enable stable gene expression in immunocompetent animals. 30 Direct injection into the blood stream and transduction of specific cells would facilitate the application of gene therapy to the treatment of many diseases. Because most diseases, both acquired and hereditary, either originate in specific cells or manifest their clinical phenotypes in specific tissues, the gene therapy vectors could be delivered where they would be most effective. Targeted vectors that circulate in the system and home to specific tissues would allow early therapeutic intervention in diseases such as cancer, in which early treatment of metastases is of considerable therapeutic value. In theory, using the technology described here, metastases could be targeted even before they can be visualized by current technologies, as was indeed the case in two animals in which transgene expression was detected prior to X-ray manifestation of the tumor.
A further understanding of vector trafficking and host response will also be necessary for the optimization and future implementation of this technology in the clinic.
MAterIAls And MetHods
Cells. 293T, HeLa, HepG2 and human primary fibroblasts CCD-1064SK were obtained from American type culture collection and cultured according to American type culture collection recommendations. Human umbilical vein endothelial cells were obtained from AllCells (Emeryville, CA) and grown in human umbilical vein endothelial cell basal medium plus stimulatory supplement (AllCells, Emelyville, CA). Prostate cancer cell lines LNCaP and LPSCA4 were cultured in RPMI 1640 (Invitrogen, Carlsbad, CA). LPSCA4 cells are clones of LNCaP cells stably transfected with PSCA referred to as LNCaP-PSCA in reference 22. Human primary PBMCs were isolated from leukopacks, Ficoll purified and cultured in RPMI with 20% fetal calf serum (Omega Scientific, Tarzana, CA), phytohemagglutinin (2.5 µg/ml), and IL-2 (20 units/ml). After 2 days, PBMCs were cultured in RPMI containing IL-2 (20 units/ml). Primary human macrophages were isolated from Ficoll purified PBMC by plastic adherence and allowed to differentiate for 7 days with granulocyte-monocyte colony stimulating factor (5 ng/ml; ReproTech, Rocky Hill, NJ) before vector transduction. LAPC-9 prostate tumor cells were derived from a human metastatic lesion to bone. 16 They do not survive ex vivo and were therefore propagated in the subcutaneous tissue of male SCID mice as described. 13, 15, 16 Plasmid construction. FUGW (self-inactivating LV carrying the Ubi-C and EGFP) was provided by David Baltimore (California Institute for Technology). The construction of FUhLucW (Ubi-C promoter driving humanized luciferase) and FUIntronRW (Ubi-c promoter driving Renilla luciferase) from FUGW has been described. 4 The PSE-BC promoter was amplified from pBCFLuc (kindly provided by L Wu, University of California-Los Angeles) by polymerase chain reaction amplification that introduced sites PacI and PinAI. These sites were used to clone the promoter into FUGW and FUhLucW to produce FPGW and FPhLucW. FUcfLW, that carries a flag-tagged luciferase, was constructed by adding the flag epitope (MDYKDDDDK) immediately 5′ of the luciferase stop codon of FuhLucW, 4 and FPcfLW was constructed by introducing the PSE-BC promoter into FUcfLW using PacI and PinAI sites. The modified Sindbis virus envelope termed 2.2 was obtained by introducing the SGN UTR mutations previously described 20 into the Sindbis derived m168 envelope 4 to enhance infectivity of the m168 envelope.
Virus production. All LVs were produced by calcium phosphate-mediated transient transfection of 293T cells and concentrated by ultracentrifugation through a 10% sucrose cushion as previously described.
4,20
Specific In Vivo Homing of Dual-targeted Vector
Complete list of vectors. See Table 2 for a complete list of vectors.
In vitro vector transduction. 1 × 10 5 cells were treated with 200 µl of FUGW, FPGW, FUhLucW, or FPhLucW pseudotyped with either VSV-G or 2.2 envelope at a concentration of 200 ng human immunodeficiency virus (HIV) p24/ml for 2 hours at 37 °C and 5% CO 2 . 2.2 pseudotypes were transduced in the presence or absence of 1G8 monoclonal antibody (that recognizes PSCA) (1.5 µg/ml). Three days after infection, transgene expression was analyzed. For the studies of androgen inducibility of the PSE-BC promoter, medium was replaced with 10% charcoal-stripped serum for 2 days prior to infection. Following infection, the synthetic androgen methylenetrienolone (R1881; NEN Life Science Products, Boston, MA) was added to samples as indicated. EGFP expression was detected by flow cytometry using a FACScan (BD Biosciences, San Jose, CA). Luciferase expression was detected after cell lysis with the Luciferase Assay System (Promega, Madison, WI) and a Monolight 2010 luminometer, according to themanufacturer's instructions.
In vivo analysis of the specificity of the PSE-BC promoter. Mice husbandry, care and procedures were performed under the University of California Animal Research Committee guidelines. 1 × 10 6 293T or LAPC-9 cells were injected subcutaneously into the left flanks of 6-week-old naïve male SCID mice (n ≥ 5). When the tumor size was 0.5 cm in diameter, FUhLucW (VSV-G) or FPhLucW (VSV-G) (2.15 µg HIV-1 p24/mouse) were injected intratumorally. Four animals were injected with each vector and two animals were injected with only phosphate-buffered saline as negative controls. Luciferase expression from the LVs was analyzed weekly using a CCCD camera (Xenogen Corporation, Hopkinton, MA) as previously described. 4 Mice were killed by CO 2 narcosis when the tumors reached 1.5 cm in diameter. The organs from each mouse were excised and imaged immediately after extraction. Unless stated otherwise, CCCD maximum photon output measurements were analyzed.
In vivo analysis of vector background. Six-week-old naïve male SCID mice (three per group) were injected through the tail vein with FUhLucW (VSV-G) or FPhLucW (VSV-G) (2.15 µg HIV-1 p24/mouse) mixed with 10 times less FUIntronRW (VSV-G). Two mice were injected with 250 µl of phosphate-buffered saline as negative control. Firefly and Renilla luciferase expression in vivo was assessed weekly for 16 days as described (15) . In order to analyze the 2.2 envelope, three male SCID mice were injected through the tail vein with FUhLucW (2.2) + isotype control antibody (15 µg/ml) or FUhLucW (VSV-G) (3.5 µg HIV-1 p24/mouse). Luciferase expression analysis using a CCCD camera was performed once a week for 14 days. Mice were euthanized by CO 2 narcosis and their organs were extracted and imaged immediately after extraction.
Targeting of LAPC-9 bone metastases in vivo. Intratibial injection of LAPC-9 cells has been previously described. 13 After LAPC-9 cell implantation, weekly radiographs of the mice were taken starting at week 2 and going on until week 5, using a Faxitron (Field Emission Corporation, McMinniville, OR) to assess bone lesions. At 4 weeks, all of the animals injected with LAPC-9 presented osteoblastic bone lesions in the left tibia (data not shown). On days 7 and 14 after LAPC-9 implantation, mice were injected through the tail-vein with FPcfLW (VSV-G) (n = 5), FPcfLW (2.2) + isotype control antibody (2.3 µg) (n = 5), FPcfLW (2.2) + 1G8 antibody (2.3 µg) (n = 16) or phosphate-buffered saline (n = 3). Each mouse received 3.5 µg of HIV p24/injection. Luciferase expression was assessed weekly starting on the date of the first injection. Mice were killed 33 days after the first vector injection because the tumor had grown to the pre-set size limit. After sacrifice, the left hind limbs of two animals from each control group and four animals from the FPcfLW (2.2) + 1G8 group were fixed and processed for histologic analysis. Organs from the rest of the animals were extracted and homogenized. One-half was used for DNA extraction and quantitative polymerase chain reaction while the other half was used for determining luciferase activity ex vivo.
Quantitative polymerase chain reaction for in vivo analysis of background infection. Genomic DNA was isolated using a DNeasy kit (Qiagen). Quantitation of the vector copy number and mouse cell number in the DNA isolates by quantitative polymerase chain reaction, and the primers used, have been previously described. 4 The primers for the analysis of human cell number (human β-globin) were BGF1 (5′-CAACCTCAAACAGACACC ATGG-3′) and BGR1 (5′-TCCACGTCCACCTTGCCC-3′). The standard for the analysis of cell number was made using genomic DNA isolated from human primary PBMC.
Histological analysis of lentivirus vector infection.
The left hind limbs of two animals from each control group and four animals from the FPcfLW (2.2) + 1G8 group of the LAPC-9 bone metastases-targeting experiment were fixed in 10% formalin phosphate overnight at 4 °C. The tissues were then decalcified in Surgipath decalcifier II (Surgipath, Richmond, IL) for 6 hours, rinsed in water for 15 minutes and treated with 30% sucrose for 48 hours at 4 °C. The tissues were then embedded in O.C.T. for quick freezing in liquid nitrogen. Cryostat sections (4 μm) were cut from the frozen limbs. Slides from each sample were stained with α-flag (Sigma) and α-hPARP (human nuclear protein polyadenosine diphosphate-ribose polymerase) (Santa Cruz Biotechnology, Santa Cruz, CA) antibodies and 4′,6-diamidino-2-phenylindole using a tyramide signal amplification kit (Invitrogen, Carlsbad, CA). Staining procedure is detailed in Supplementary Materials and Methods. Confocal fluorescence images were taken on a Leica TCS-SP MP Confocal and Multiphoton Inverted Microscope (Leica Microsystems Inc., Heidelberg, Germany) and processed using Leica Confocal Software.
Statistical analyses. Differences in luciferase expression in vivo between experimental groups were assessed using a two-sided Wilcoxon Rank sum test. P ≤ 0.05 was considered as statistically significant. Abbreviations: EGFP, enhanced green fluorescent protein; Ubi-C, ubiquitin-C; VSV-G, vesicular stomatitis virus glycoprotein.
